Figure 1.

In vivo PIM1 inhibition in PIM1high and PIM1^low T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LBL) patients. (A) Schematic representation of the in vivo treatment schedule used for the PIM inhibitors TP-3654 and AZD1208; 4 mice per group were used. (B) Percentage of human CD45⁺ (%hCD45) cells in peripheral blood during treatment (left) and spleen weight of the different treatment groups after completion of treatment (right). ^*P<0.05; ^**P<0.01; ^***P<0.005. (C) Delayed tumor development in TCRβ-PIM1⁺ T-LBL and TLX3⁺ PIM1^high T-ALL xenografts after short-term in vivo PIM1 inhibition with TP-3654; 4 mice per group were used. (D) Short-term response of an SIL-TAL1⁺ PIM1^low T-ALL to PIM1 inhibition using TP-3654; 4 mice per group were used.